Mainstay Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mainstay Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-150	Closed	-$14K	–	379
2018 Q3	$14K	Hold	150	–	–	0.01%	318
2018 Q2	$14K	Hold	150	–	–	0.01%	303
2018 Q1	$13K	Hold	150	–	–	0.01%	232
2017 Q4	$13K	Buy	+150	New	+$12.6K	0.01%	250

Other funds holding XBI

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Mainstay Capital Management's XBI Position: Q4 2018 in Review

Mainstay Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 150 shares — an estimated $14K sold.

Mainstay Capital Management first reported a position in XBI in Q4 2017 and held it in 4 quarters. The position peaked at $14K in Q3 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

Mainstay Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
Mainstay Capital Management sold 150 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $14K.
Mainstay Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 4 quarters.
Mainstay Capital Management's State Street SPDR S&P Biotech ETF position peaked at $14K in Q3 2018.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.